View Financial HealthEntropy Neurodynamics 배당 및 자사주 매입배당 기준 점검 0/6Entropy Neurodynamics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-16.2%자사주 매입 수익률총 주주 수익률-16.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listing공시 • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australia공시 • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.공시 • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.공시 • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 TYPT.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: TYPT.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Entropy Neurodynamics 배당 수익률 vs 시장TYPT.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (TYPT.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (TYPT.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 TYPT.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 TYPT.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 TYPT.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: TYPT.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 00:57종가2026/05/27 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Entropy Neurodynamics Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael HigginsLadenburg Thalmann & Company
공시 • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listing
공시 • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australia
공시 • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.
공시 • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.
공시 • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.